Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Haoran Xia, Gening Jiang, Wenxin He et al.|Signal Transduction and Targeted Therapy|2024

Cited by 30